Terry O’Reilly

Scp776, A Novel IGF‐1 Fusion Protein for Acute Therapy to Promote Escape From Apoptosis in Tissues Affected by Ischemic Injury: 2 Randomized Placebo‐Controlled Phase 1 Studies in Healthy Adults

Samuel J. Pfaff, Terry O’Reilly, Yan Zhang, Walter L. Olsen et autres

us (code pays fourni par la source)

Thorough QT/QTc study to evaluate the effect of a single supratherapeutic dose of islatravir on QTc interval prolongation in healthy adults

Randolph P. Matthews, Yang Liu, Catherine Z. Matthews, Kristin L. Butterfield et autres

us (code pays fourni par la source)

Single‐ and Multiple‐Dose Pharmacokinetics of Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, in Healthy Adults

Jesse C. Nussbaum, Azher Hussain, P. Butera, Anthony Ford et autres

us, ch, nz (code pays fourni par la source)

The effects of once-daily opicapone 50 mg on the pharmacokinetics of levodopa administered as carbidopa/levodopa extended-release capsules: an open-label study

Olga Klepitskaya, Arjun Vijan, Kurt Olson, Terry O’Reilly et autres

us (code pays fourni par la source)

A Randomized, Double‐Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers

Jimin Lee, Robert Lester, Terry O’Reilly, Ezra R. Lowe et autres

us (code pays fourni par la source)

GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar

Oliver von Richter, Terry O’Reilly, Davide Guerrieri, Jamie Fan et autres

de, us (code pays fourni par la source)

Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial

Jonathan A. Robbins, Dereck Tait, Qinlei Huang, Sheri Dubey et autres

us (code pays fourni par la source)

Pharmacokinetics and Macrophage Inhibitory Cytokine‐1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT‐232) in Fed and Fasted Healthy Subjects

Shekman Wong, Cecile M. Krejsa, Dana Lee, Anna L. Harris et autres

us (code pays fourni par la source)

P029 Pharmacokinetic/Pharmacodynamic Analysis of Amiselimod, a Selective Sphingosine 1-Phosphate Receptor Modulator, in Healthy Subjects: Results From a Phase 1 Study

Jimin Lee, R. J. G. Lester, Terry O’Reilly, Ezra R. Lowe et autres

us (code pays fourni par la source)

SAFETY OF AMISELIMOD IN HEALTHY SUBJECTS: RESULTS FROM A PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Stephen B. Hanauer, Terry O’Reilly, Robert M. Lester, Neal E. Slatkin et autres

SAFETY OF AMISELIMOD IN HEALTHY SUBJECTS: RESULTS FROM A PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Stephen B. Hanauer, Terry O’Reilly, R. J. G. Lester, Neal E. Slatkin et autres

Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials

Carine Beysen, Patricia Schroeder, Eric Wu, Julie Brevard et autres

us, se (code pays fourni par la source)